Kenneth J Pienta, MD
Grasso CS et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487(7406):239-43. Abstract
Pienta KJ. Successfully accelerating translational research at an academic medical center: The University of Michigan-Coulter translational research partnership program. Clin Transl Sci 2010;3(6):316-8. Abstract
Roychowdhury S et al. Personalized oncology through integrative high-throughput sequencing: A pilot study. Sci Transl Med 2011;3(111):111ra121. Abstract
Eleni Efstathiou, MD, PhD
Efstathiou E et al. Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate 2013;73(2):153-61. Abstract
Efstathiou E et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 2012;30(6):637-43. Abstract
Efstathiou E et al. MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: A preliminary report. Genitourinary Cancers Symposium 2011;Abstract 4501.
William K Oh, MD
Bauer JA et al. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin Cancer Res 2010;16(2):681-90. Abstract
Berthold DR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242-5. Abstract
Hasmats J et al. Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. Gene 2012;506(1):62-8. Abstract
Mita AC et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15(2):723-30. Abstract
Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20. Abstract
Sartor AO et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). Genitourinary Cancers Symposium 2010;Abstract 9.
Tannock IF et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract
Zhao L et al. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Research 2009;69(19):7696-703. Abstract
Nima Sharifi, MD
Attard G et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009;69(7):2912-8. Abstract
Chen CD et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-9. Abstract
Chen T et al. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 2000;60(8):2132-5. Abstract
De Bono JS et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005. Abstract
Edwards J et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89(3):552-6. Abstract
Gelmann EP et al. Molecular biology of the androgen receptor. J Clin Oncol 2002;20(13):3001-15. Abstract
McPhaul MJ. Mechanisms of prostate cancer progression to androgen independence. Best Pract Res Clin Endocrinol Metab 2008;22(2):373-88. Abstract
Mellinghoff IK et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004;6(5):517-27. Abstract
Montgomery BR et al. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 2008;68(11):4447-54. Abstract
Mousses S et al. Failure of hormone therapy in prostate cancer involves systemic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001;20(46):6718-23. Abstract
Ryan CJ et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368(2):138-48. Abstract
Titus MA et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11(13):4653-7. Abstract
Andrew J Armstrong, MD, ScM
Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011;364(21):2055-8. Abstract
Armstrong AJ et al. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol 2012;30(27):3402-7. Abstract
Armstrong AJ et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 2011;9(8):997-1007. Abstract
Armstrong AJ et al. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res 2010;16(11):3057-66. Abstract
Armstrong AJ et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clin Cancer Res 2007;13(21):6396-403. Abstract
Attard G et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009;69(7):2912-8. Abstract
De Bono JS et al. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res 2008;14(20):6663-73. Abstract
Grasso CS et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487(7406):239-43. Abstract
Halabi S et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21(17):1232-7. Abstract
Liu W et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15(15):559-65. Abstract
Olmos D et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: A prospective, two-stage study. Lancet Oncol 2012;13(11):1114-24. Abstract
Ross RW et al. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: A prospective study. Lancet Oncol 2012;13(11):1105-13. Abstract
Scher G et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. Proc ASCO 2011;Abstract LBA4517.
Shaffer DR et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13(7):2023-9. Abstract
Sieuwerts AM et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009;101(1):61-6. Abstract
Smaletz O et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002;20(19):3972-82. Abstract